Join CTTC | Print Page | Contact Us | Sign In
CTTC 2020 Webinar - Mitchell Sabloff
Register Tell a Friend About This EventTell a Friend
CTTC 2020 Webinar - Mitchell Sabloff

 Export to Your Calendar 8/5/2020
When: August 5, 2020
9:00am PT/12:00pm ET
Where: Canada


Online registration is available until: 8/4/2020
« Go to Upcoming Event List  

August 5, 2020
9:00am PT/12:00pm ET

 

Can Older Rel/Ref AML Patients with Active Disease be Transplanted?

Preliminary Midpoint Results from the Pivotal Phase 3 SIERRA Trial, open at The Ottawa Hospital


Mitchell Sabloff
, MD (Ottawa Hospital Leukemia Program, Ottawa, Canada)

 

 

This webinar is sponsored by  

 

We have updated our webinar registration process. After completing your registration on our website you will be asked to finalize your registration with GoToWebinar to receive a confirmation email containing all of the information about joining the webinar.

 


Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for our ARCs is targeted conditioning, which is intended to selectively kill patient's cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, CAR-T and other cell therapies or gene therapy to enable engraftment of these transplanted cells with minimal toxicities. With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Our lead product candidate, Iomab-B (131I apamistamab) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SIERRA trial is over fifty percent enrolled and promising single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings. Beyond Iomab-B, we are developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Underpinning our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform. This is where our intellectual property portfolio of over 120 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARCs and ARC combinations to bolster our pipeline for strategic purposes. Our AWE technology platform is currently being utilized in a collaborative research partnership with Astellas Pharma, Inc.

 

This website is sponsored by an 
unrestricted educational grant from: